Harrow (NASDAQ:HROW) Reaches New 52-Week High at $40.38

Harrow, Inc. (NASDAQ:HROW)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $40.38 and last traded at $40.13, with a volume of 96666 shares changing hands. The stock had previously closed at $39.48.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Craig Hallum boosted their target price on shares of Harrow from $30.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 9th. Lake Street Capital boosted their price objective on shares of Harrow from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, June 3rd. Finally, B. Riley increased their target price on Harrow from $29.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, August 9th.

Harrow Trading Up 3.1 %

The company has a current ratio of 2.60, a quick ratio of 2.43 and a debt-to-equity ratio of 3.18. The business has a 50 day simple moving average of $25.45 and a two-hundred day simple moving average of $17.18. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -45.46 and a beta of 0.77.

Institutional Trading of Harrow

Several hedge funds and other institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its stake in Harrow by 5.0% during the second quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company’s stock valued at $248,000 after purchasing an additional 567 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Harrow by 6.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock valued at $221,000 after buying an additional 1,033 shares during the period. nVerses Capital LLC bought a new stake in shares of Harrow during the 2nd quarter valued at about $33,000. BNP Paribas Financial Markets grew its position in shares of Harrow by 12.7% during the 1st quarter. BNP Paribas Financial Markets now owns 16,941 shares of the company’s stock valued at $224,000 after buying an additional 1,912 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in Harrow by 2,730.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after acquiring an additional 2,048 shares during the period. 72.76% of the stock is owned by institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.